Onconephrology contributor

Perazella, Mark A

Primarily Anticancer drug nephrotoxicityHonor roll · #11

Clinical papers

2,526

Citations (iCite)

13 / 27

First / senior author

2002–2026

Active years

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

Anticancer drug nephrotoxicity33

Onco-nephrology (general)18

Checkpoint-inhibitor kidney injury10

Myeloma cast nephropathy5

Cellular therapy renal effects4

Anti-VEGF / TKI renal effects2

MGRS & paraprotein kidney disease2

Tumor lysis & electrolytes1

Agents they study

Catalog agents whose clinical kidney literature lists Perazella among the leading contributors.

Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)11 Methotrexate (high-dose)4 Pamidronate3 Mitomycin C2

Verify

Representative recent papers, and this author’s full PubMed bibliography.

41881107 41866123 41361704 41247096 41105138 40630288 All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers (regenerated 2026-07-08). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.